PHRX (Pharmagen) Total Current Liabilities: $8.30 Mil (As of Mar. 2014)


What is Pharmagen Total Current Liabilities?

Pharmagen PHRX -90.00% Total Current Liabilities is $8.30 Mil as of Mar. 2014.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Pharmagen's total current liabilities for the quarter that ended in Mar. 2014 was $8.30

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Pharmagen Total Current Liabilities Related Terms

Pharmagen Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pharmagen's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagen Total Current Liabilities Chart

Pharmagen Annual Data
Trend Jun10 Jun11 Dec12 Dec13
Total Current Liabilities
0.11 0.20 2.44 8.10

Pharmagen Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.46 7.02 8.00 8.10 8.30

Pharmagen Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Pharmagen's Total Current Liabilities for the fiscal year that ended in Dec. 2013 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.57+3.67
+Other Current Liabilities+Current Deferred Liabilities
=2.859+0
=8.10

Pharmagen's Total Current Liabilities for the quarter that ended in Mar. 2014 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.899+4.939
+Other Current Liabilities+Current Deferred Liabilities
=1.457+0
=8.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $8.30 Mil mean?
Pharmagen (PHRX) has a Total Current Liabilities of $8.30 Mil as of Mar. 2014. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Pharmagen and its competitors.
Is Pharmagen's Total Current Liabilities too high?
Pharmagen's current Total Current Liabilities is $8.30 Mil.
How does Pharmagen's Total Current Liabilities compare to FZMD and SNYR?
Pharmagen's Total Current Liabilities of $8.30 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Distribution company?
A good Total Current Liabilities depends on the Medical Distribution industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Pharmagen and its competitors. Pharmagen's current Total Current Liabilities is $8.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagen stock overvalued right now?
Pharmagen (PHRX) has a current Total Current Liabilities of $8.30 Mil. The current Total Current Liabilities is $8.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Pharmagen (PHRX), the current Total Current Liabilities is $8.30 Mil as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagen Business Description

Address 9337 Fraser Avenue, Silver Spring, MD, USA, 20910
Pharmagen Inc as a distributor of specialty drugs, compounding and admix pharmacy, and producer of over-the-counter branded multivitamins to the healthcare provider market. The company distributes hard-to-find and specialty drugs to the healthcare provider market throughout the United States, while functioning as an aggregator of real-time market demand for these products.